MedTrace Logo

REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

NCT06777368 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 225

Last updated 2026-02-12

No results posted yet for this study

Summary

The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR).

Conditions

  • Aortic Stenosis

Interventions

DEVICE

Medtronic TAV

Medtronic TAV where commercially available

DEVICE

Edwards TAV

Edwards TAV where commercially available.

Sponsors & Collaborators

  • Medtronic Cardiovascular

    lead INDUSTRY

Principal Investigators

  • Gregory Fontana, MD · Los Robles Regional Medical Center

  • Guilherme Attizzani, MD · UH, Cleveland Medical Center

  • Basel Ramlawi · Lankenau Heart Institute

Eligibility

Min Age
18 Years
Max Age
105 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-06
Primary Completion
2029-03-31
Completion
2033-07-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06777368 on ClinicalTrials.gov